BioSpace News Archive

VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer.

Halberd Corporation on March 29th met with five representatives from the Centers for Disease Control and Prevention.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”) today reported its financial results for the full year ended December 31, 2022 and provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a leader in the discovery of therapeutic peptide hits, announced today that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.

BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, provided a business update for the year ended December 31, 2022 and reported on recent corporate developments.

Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, announced that on March 30, 2023 the company closed the private placement of an aggregate of 4,975,608 shares of its common stock at a purchase price of $0.41 per share for aggregate gross proceeds of $2.04 million.

Comera Life Sciences Holdings, Inc. announced the expansion of its patent portfolio with one new patent granted in South Korea and two Notices of Allowance in the U.S. and Japan covering expansion of claims and exclusive rights pertaining to certain excipients in its proprietary SQore™ platform.

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, announced that Becky Marson has joined the company as its chief people and performance officer.

Assure Holdings Corp., a provider of intraoperative neuromonitoring and remote neurology services, reported financial results for the full year ended December 31, 2022.